News

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and ...

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth, Palo Alto

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

Novo Nordisk: Market Still Pricing It At Crisis Valuations

Novo Nordisk is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels ...

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...